Goldman Sachs Maintains Buy Rating on Abbott Laboratories (ABT) Stock
Key takeaways
- Goldman Sachs Maintains Buy Rating on Abbott Laboratories (ABT) Stock Bob Karr Mon, June 8, 2026 at 11:16 PM GMT+7 1 min read ABT Abbott Laboratories (NYSE:ABT) is one of the Best Blue Chip Stocks Under $100 to Buy Now.
- Furthermore, the analyst hinted at a visible path focused on margin expansion and earnings leverage in 2026 and beyond, amid potential improvement in sentiment as execution becomes evident.
- Abbott Laboratories (NYSE:ABT) is engaged in discovering, developing, manufacturing, and selling health care products.
Goldman Sachs Maintains Buy Rating on Abbott Laboratories (ABT) Stock Bob Karr Mon, June 8, 2026 at 11:16 PM GMT+7 1 min read ABT Abbott Laboratories (NYSE:ABT) is one of the Best Blue Chip Stocks Under $100 to Buy Now. On May 27, analyst David Roman from Goldman Sachs maintained a “Buy” rating on the company’s stock and reduced the price objective to $113.00 from $121.00. The analyst’s rating is supported by several factors that highlight improvements in fundamentals and an attractive risk-reward profile. Notably, the analyst pointed to the clear bridge from softer early-2026 trends to healthier growth later, thanks to the accelerated sales in Nutrition, Devices, and Diagnostics, and specific product ramps like Libre and new Electrophysiology launches.
Furthermore, the analyst hinted at a visible path focused on margin expansion and earnings leverage in 2026 and beyond, amid potential improvement in sentiment as execution becomes evident. While the analyst acknowledged the challenges that Abbott Laboratories (NYSE:ABT) might face in the near-term, the current valuation remains compelling relative to the company’s growth profile. Also, optional catalysts, such as favorable reimbursement decisions and share repurchases, can result in further upside, added Roman.
Abbott Laboratories (NYSE:ABT) is engaged in discovering, developing, manufacturing, and selling health care products.